InMed Pharmaceuticals INM Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, InMed Pharmaceuticals insiders bought $1.35 million of stock on the open market (890.8K shares) and made no open-market sales.

• By number of insiders, InMed Pharmaceuticals saw 2 insiders buy on the open market over the past 12 months and none sell.
• Among InMed Pharmaceuticals' insiders, the largest open-market purchases in the past 12 months were by Adar1 Capital Management, LLC (10% owner), totaling $912,743 (614.48K shares), most recently on October 8, 2026.
• Per Business Quant data, InMed Pharmaceuticals insiders hold 1.77Mn shares in total based on their latest Form 4 filings, up 10.39% from 1.6Mn shares at the end of Q2 2026.
• By type of ownership, INM insiders hold 0.27% of their shares directly (4.72K shares) and 99.73% indirectly (1.76Mn shares).
• The insider holdings in InMed Pharmaceuticals belong to 5 insiders who have reported on Form 4 within the past two years.
• INM's largest insider holders by reported holdings are Adar1 Capital Management, LLC (10% owner, 945.92K shares), Vivo Opportunity, LLC (10% owner, 818.08K shares) and Eric A. Adams (President & CEO, 2.2K shares).
• The holding of Adar1 Capital Management, LLC makes up 53.48% of all shares held by InMed Pharmaceuticals insiders.
• Institutions held 50.52% of InMed Pharmaceuticals' outstanding shares in their Q2 2026 13F filings, insiders about 33.13% based on their latest Form 4 filings, and other investors, including the public, the remaining 16.35%.
• Over the past 12 months, 11 insiders reported transactions in InMed Pharmaceuticals stock in 22 Form 4 filings.
• These insider figures for InMed Pharmaceuticals are based on Form 4 filings through October 8, 2026.